Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | GPR27 | Q9NS67 | 4/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1402980 | 0.90 | MAPT (0.44) | MAPTTP53MCL1BCL2L1GPR27 | |
| SCHEMBL3632786 | 0.88 | MAPT (0.47) | MAPTTP53MCL1BCL2L1GPR27 | |
| SCHEMBL1402901 | 0.88 | MAPT (0.47) | MAPTTP53MCL1BCL2L1GPR27 | |
| SCHEMBL1403484 | 0.85 | BCL2L1 (0.49) | MAPTTP53MCL1BCL2L1HDAC3 | |
| SCHEMBL1403124 | 0.84 | CPT1A (0.57) | MAPTMCL1GPR27AVPR2HDAC1 | |
| SCHEMBL1403194 | 0.83 | CA1 (0.49) | MAPTHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1403192 | 0.83 | CA1 (0.49) | MAPTHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2555737 | 0.77 | EIF2AK2 (0.42) | MAPTWDR5 | |
| SCHEMBL2555735 | 0.77 | EIF2AK2 (0.42) | MAPTWDR5 | |
| SCHEMBL1402863 | 0.75 | ITGA1 (0.49) | MAPTMCL1GPR27AVPR2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292593-A2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2011-03-09 | — | — | EP | disclosed |
| US-7407988-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7183298-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-02-27 | — | — | US | disclosed |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| US-20050107445-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | PROLIFIX LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| US-6888027-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-05-03 | — | — | US | disclosed |
| US-20050085515-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPO TARGET UK LIMITED, (GB) | 2005-04-21 | — | — | US | disclosed |
| US-20040077726-A1 | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | SWK FUNDING LLC | 2004-04-22 | — | — | US | disclosed |
| EP-1328510-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LTD. (GB) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002030879-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107445-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | MAPT 2415/4885TP53 532/4885MCL1 1362/4885 |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | MAPT 2415/4885TP53 532/4885MCL1 1362/4885 |
| US-20040077726-A1 | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC2 | MAPT 3107/4885TP53 580/4885MCL1 2014/4885 |
| US-20050085515-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | MAPT 2415/4885TP53 532/4885MCL1 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.